Expression of mTOR and its relationship with prognosis of breast cancer:a Meta-analysis / 吉林大学学报(医学版)
Journal of Jilin University(Medicine Edition)
; (6): 783-788, 2016.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-494396
Responsible library:
WPRO
ABSTRACT
Objective:
To explore the expression of mammalian target of rapamycin (mTOR)and its relationgship with the prognosis of breast cancer,and to provide evidence-based basis for the using of mTOR inhibitor in the treatment of breast cancer.Methods:
A systemical literature search was conducted based on the following databasesPubMed,EMBbase,Cochrane Library,ISI Web of Science,and CNKI up to November 24,2015.The outcome measures were hazard ratio (HR)with 95% confidence interval (CI) for the association between the mTOR expression and the prognosis of patients with breast cancer.The primary end points including disease-free survival (DFS ), and overall survival (OS ). STATA 12.0 was used to conduct the statistical analysis.Results:
A total of seven cohort studies,1 758 patients were included. The risk of recurrence and metastasis of the breast cancer patients with positive expression of mTOR was 2.05 times of the patients with negative expression of mTOR (HR= 2.05, 95% CI 1.01 - 4.13,P = 0.003);the risk of death in the breast cancer patients with positive expression of mTOR was 2.63 times of the patients with negative expression of mTOR (HR = 2.63, 95%CI1.45-4.80,P = 0.736).Conclusion:
The positive expression of mTOR can significantly increase the recurrence,metastasis and death risk of the patients with breast cancer.
Full text:
Available
Health context:
SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases
Health problem:
Breast Cancer
Database:
WPRIM (Western Pacific)
Type of study:
Observational study
/
Prognostic study
/
Systematic review
Language:
Chinese
Journal:
Journal of Jilin University(Medicine Edition)
Year:
2016
Document type:
Article